Chronic Obstructive Pulmonary Disease (COPD) Treatment Market to Grow at a CAGR of 5.8% from 2025 to 2029
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Future Market Size Estimation For The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Covering 2025–2034?
The chronic obstructive pulmonary disease (copd) treatment market has demonstrated steady expansion in recent years. Its valuation is set to increase from $20.84 billion in 2024 to $21.73 billion in 2025, driven by a compound annual growth rate (CAGR) of 4.3%. Historically, this growth can be ascribed to factors such as the smoking epidemic and tobacco use, breakthroughs in inhalation therapies, effective awareness campaigns enabling early diagnosis, governmental programs aimed at respiratory health, and continued research and development in the field of pulmonology.
The chronic obstructive pulmonary disease (copd) treatment market is poised for significant expansion over the next few years. It is projected to reach a valuation of $27.22 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.8%. This anticipated growth is primarily driven by factors such as personalized medicine and biomarker research, the introduction of biologic therapies and targeted interventions, increasing awareness of air quality concerns and environmental influences, global initiatives aimed at smoking cessation, and collaborative efforts in drug development. Key trends expected to shape the market during this period include the adoption of digital health solutions for COPD management, the advancement of biologic therapies for COPD, the proliferation of personalized medicine, the development of combination therapies and advanced inhalers, a focus on early diagnosis and intervention, and the expansion of pulmonary rehabilitation programs.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp
Which Major Market Drivers Are Shaping The Future Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
The increasing occurrence of lung disease is anticipated to drive the expansion of the chronic obstructive pulmonary disease (COPD) treatment market. Lung disease is defined as a condition that impacts the lungs, hindering their proper operation. The most frequently encountered lung diseases include asthma, COPD, and lung cancer. Chronic obstructive pulmonary disease (COPD) treatment is primarily utilized to address lung disease, reduce the progression of the condition, manage symptoms, and avert lung damage by employing various inhalers and drugs. For instance, in September 2022, as reported by the global initiative for Chronic obstructive lung disease (GOLD), a US-based non-profit organization, 3.2 million people per year die from the chronic obstructive pulmonary disease (COPD), which affects an estimated 200 million individuals. Moreover, asthma impacted 262 million people globally in 2022, and these numbers are projected to rise. Furthermore, in 2023, data from the LUNGevity Foundation, another US-based non-profit organization, indicates that 127,000 Americans will die in the US each year due to lung cancer. Therefore, the rising prevalence of lung disease is a significant factor propelling the growth of the chronic obstructive pulmonary disease (COPD) treatment market.
What Are The Major Segment Categories Driving The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Growth?
The chronic obstructive pulmonary disease (copd) treatment market covered in this report is segmented –
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Combination Therapy: Long-Acting Beta-Agonists (LABA) + Inhaled Corticosteroids (ICS), Long-Acting Muscarinic Antagonists (LAMA) + LABA, Triple Therapy (LAMA + LABA + ICS)
2) By Bronchodilators: Short-Acting Beta-Agonists (SABA), Long-Acting Beta-Agonists (LABA), Long-Acting Muscarinic Antagonists (LAMA)
3) By Corticosteroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Injectable Corticosteroids
4) By Phosphodiesterase Type 4 Inhibitor: Roflumilast, Other PDE4 Inhibitors
5) By Mucokinetics: Expectorants, Mucolytics
6) By Other Drug Classes: Antibiotics, Antivirals, Antifungal Agents
Which Key Trends Are Expected To Influence The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market In The Coming Years?
A significant trend gaining traction in the chronic obstructive pulmonary disease (COPD) treatment market is product innovation. Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market are concentrating on creating novel products to maintain their competitive standing. As an illustration, in April 2022, GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and biotechnology enterprise, introduced Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol), marking the inaugural single-inhaler triple treatment (SITT) available for individuals in India suffering from chronic obstructive pulmonary disease (COPD). Trelegy Ellipta serves as a maintenance medication, designed to manage and avert the manifestations of chronic obstructive pulmonary disease (COPD) in people 18 years of age and older. Its action mimics natural corticosteroid hormones, diminishing immune system activity by binding to specific receptors on certain immune cell types. Furthermore, it assists in alleviating airway inflammation within the lungs, thereby facilitating easier breathing.
Who Are The Major Companies Operating In The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market?
Major companies operating in the chronic obstructive pulmonary disease (COPD) treatment market include Almirall S.A., AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Sanofi S.A, Theravance Biopharma Inc., Verona Pharmaceuticals plc, Alcon Laboratories Inc., Amgen Inc., Apotex Inc., Aurobindo Pharma Limited, Biocon Limited, Biogen Inc., Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals plc, Lupin Limited, Meda AB, Mundipharma International Limited, Pfizer Inc.
Download The Full Report For Exclusive Market Findings:
How Does The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Perform Across Key Geographic Regions?
North America was the largest region in the chronic obstructive pulmonary disease (COPD) treatment market in 2024.Asia-Pacific is expected to be the global chronic obstructive pulmonary disease (COPD) treatment market report during the fastest-growing region in the forecast period. The regions covered in the chronic obstructive pulmonary disease (COPD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=10054&type=smp
Browse Through More Reports Similar to the Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market 2025, By The Business Research Company
Gastrointestinal Bleeding Treatment Devices Global Market Report 2025
Gastrointestinal Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastrointestinal-devices-global-market-report
Medical Equipment Maintenance Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/medical-equipment-maintenance-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
